Safety of anti‐SARS‐CoV‐2 messenger RNA vaccine in lung cancer patients undergoing anticancer chemotherapy: A multicenter, prospective, observational, patient‐reported outcome study

BACKGROUND: COVID‐19 incidence is high in patients with cancer. The fatality rate was high for the Delta variant, necessitating infection prevention by vaccination. This study evaluated the safety of a SARS‐CoV‐2 vaccine in patients with advanced lung cancer receiving anticancer therapy. METHODS: We...

Descripción completa

Detalles Bibliográficos
Autores principales: Harada, Daijiro, Tamura, Tomoki, Ninomiya, Kiichiro, Kubo, Toshio, Kuyama, Shoichi, Tachibana, Sayaka, Inoue, Koji, Chikamori, Kenichi, Kudo, Kenichiro, Ochi, Nobuaki, Maeda, Yoshinobu, Kiura, Katsuyuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870727/
https://www.ncbi.nlm.nih.gov/pubmed/36404396
http://dx.doi.org/10.1111/1759-7714.14737

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9870727/
https://www.ncbi.nlm.nih.gov/pubmed/36404396
http://dx.doi.org/10.1111/1759-7714.14737

Ejemplares similares